Vast Granted Qualified Infectious Disease Product Designation from the FDA
Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration has ...
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
The Lancet3d
Targeting neutrophil serine proteases in bronchiectasis—where are we now?
Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...
Everyone with these 27 NHS health conditions can still get £812 DWP PIP benefits
The DWP's PIP benefits are still available despite potential changes and could get you £812 a month if you have one of these ...
EurekAlert!16d
Thirty-three centers join new Bronchiectasis and NTM Care Center Network
The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new Bronchiectasis and NTM Care Center ...
University of California, San Francisco16d
UCSF Among First in U.S. to Receive New Pulmonary Care Designation
The Bronchiectasis and NTM Association has accepted UC San Francisco (UCSF) into its Bronchiectasis and NTM Care Center Network (CCN), recognizing UCSF’s dedication to providing high-quality medical ...
Healio17d
25.4% of patients with bronchiectasis had symptoms for more than 10 years before diagnosis
This study cohort was made up of 71.3% U.K. patients with bronchiectasis. Referral to pulmonary rehabilitation was presented to 19.6% of patients. Prior to being diagnosed with bronchiectasis ...
Frontiers1mon
Impact of physical activity on all-cause mortality in individuals with non-cystic fibrosis bronchiectasis
Background: Little information is available regarding whether active physical activity lowers mortality risk in individuals with bronchiectasis. Methods: We used the Korean National Health Insurance ...
Investing1mon
FDA sets PDUFA date for Insmed's bronchiectasis drug
This Phase 3 study is the largest ever conducted for bronchiectasis, a chronic lung condition characterized by the widening of the airways, leading to recurrent infections, inflammation ...
Business Wire1mon
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO ...